<DOC>
	<DOCNO>NCT00106158</DOCNO>
	<brief_summary>The purpose study assess safety repeat dose cholesterol-bearing hydrophobized pullulan ( CHP ) NY-ESO-1 protein ( CHP-NY-ESO-1 ) describe NY-ESO-1 specific-humoral cellular immune response immunization CHP-NY-ESO-1 patient cancer express NY-ESO-1 .</brief_summary>
	<brief_title>Safety Study NY-ESO-1 Protein Vaccine Treat Cancer Expressing NY-ESO-1</brief_title>
	<detailed_description>NY-ESO-1 isolate serological analysis recombinant cDNA expression library ( SEREX ) , use tumor mRNA autologous serum esophageal cancer patient . Reverse transcription-polymerase chain reaction ( RT-PCR ) analysis show NY-ESO-1 display typical expression pattern CT antigens . NY-ESO-1 mRNA express testis normal tissue test various type cancer , include lung cancer , breast cancer , malignant melanoma bladder cancer . LAGE-1 identify representational difference analysis reveal display 84 % amino acid homology NY-ESO-1 . In case , expression LAGE-1 parallel expression NY-ESO-1 . Since testis immune privilege organ HLA molecule express , antigen consider tumor-specific . Because frequent NY-ESO-1 mRNA expression high immunogenicity advance cancer , NY-ESO-1 attractive target molecule cancer vaccine . Current therapy advance cancer limit effectiveness . The idea vaccination NY-ESO-1 protein cancer patient tumor express NY-ESO-1 mRNA base two finding : 1 ) number CD8+ T cell epitope identify NY-ESO-1 molecule limit bind HLA-A0201 , A31 , Cw3 Cw6 . These HLA subtypes carry minor Japanese population ; 2 ) CD8+ T cell response specific NY-ESO-1 polyclonal . Protein vaccination may induce immune response effectively tumor express NY-ESO-1 peptide immunization .</detailed_description>
	<criteria>Histologically proven cancer Confirmed NYESO1 expression No effective therapy available 4 week since conventional therapy start current protocol Performance status &lt; 2 ( ECOG scale ) Age &gt; 18 Able willing give write informed consent Serious illness Metastatic diseases central nervous system Concomitant systemic treatment corticosteroid , antihistaminic drug NSAIDs HIV positive Mental impairment may compromise ability give write informed consent Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>cancer/testis antigen</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>recombinant protein</keyword>
</DOC>